AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|
16.3 C
New York
Wednesday, November 4, 2026

Tag: FVT TRI

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective...

Mozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual Meeting

Presentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3...

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data  PITTSBURGH, Aug. 1, 2025 /PRNewswire/...

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD...

-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D., Professor of...

Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

Presentation of Data from Clinical Trial of Aspen's Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson's Disease SAN DIEGO, June 9, 2025 /PRNewswire/ --...

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5,...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFVT TRI